Basic Information

• CAS Number: 941678-49-5

• English Name: Ruxolitinib

Physical and Chemical Properties

• Molecular Formula: C17H18N6

• Molecular Weight: 306.36

• EINECS Number: 1312995-182-4

• Density: 1.40

• Boiling Point: 592.6±50.0 °C at 760 mmHg

• Refractive Index: 1.747

• Flash Point: 312.2±30.1 °C

• Vapor Pressure: 0.0±1.7 mmHg at 25°C

• Solubility: Soluble in aqueous buffers across a pH range of 1-8; In water, 100.8 mg/L at 25°C (estimated)

• Stability: Stable under recommended storage conditions

Uses

• Pharmacological Action: Ruxolitinib is the first orally administered drug approved by the US Food and Drug Administration (FDA) for the treatment of myelofibrosis. It is a tyrosine kinase inhibitor, specifically a small molecule inhibitor of JAK1 and JAK2 protein tyrosine kinases. It is indicated for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.

• Industrial Applications: As a pharmaceutical intermediate, it has important applications in the chemical and pharmaceutical industries.